blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1490024

EP1490024 - EFFERVESCENT COMPOSITIONS COMPRISING ALENDRONATE [Right-click to bookmark this link]
Former [2005/01]EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO
[2011/18]
StatusNo opposition filed within time limit
Status updated on  23.11.2012
Database last updated on 05.10.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
EffRx Pharmaceuticals SA
Avenue du Théâtre 1 c/o KPMG SA
1005 Lausanne / CH
[2011/27]
Former [2008/52]For all designated states
Effrx, Inc.
1095 Jupiter Drive, Suite 11
Jupiter, FL 33458 / US
Former [2005/01]For all designated states
Lifizz, Inc.
Suite 11, 1095 Jupiter Park Drive
Jupiter, FL 33458 / US
Inventor(s)01 / MCCALLISTER, David
11505 Fairchild Gardens Avenue
Palm Beach Gardens, FL 33410 / US
02 / ROSEN, Christer
17537 S.E. Conch Bar Avenue
Tequesta, FL 33469 / US
 [2005/20]
Former [2005/01]01 / MCCALLISTER, David
8469 Ironhorse Court
West Palm Beach, FL 33412 / US
02 / ROSEN, Christer
17537 S.E. Conch Bar Avenue
Tequesta, FL 33469 / US
Representative(s)Mai, Oppermann & Partner i.L.
Patentanwälte
John-F.-Kennedy-Strasse 4
65189 Wiesbaden / DE
[N/P]
Former [2012/03]Luderschmidt, Schüler & Partner
Patentanwälte John-F.-Kennedy-Strasse 4
65189 Wiesbaden / DE
Former [2005/01]Luderschmidt, Schüler & Partner GbR
Patentanwälte, John-F.-Kennedy-Strasse 4
65189 Wiesbaden / DE
Application number, filing date03716287.206.03.2003
[2005/01]
WO2003US06576
Priority number, dateUS2002009208306.03.2002         Original published format: US 92083
[2005/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03075884
Date:18.09.2003
Language:EN
[2003/38]
Type: A1 Application with search report 
No.:EP1490024
Date:29.12.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2003 takes the place of the publication of the European patent application.
[2004/53]
Type: B1 Patent specification 
No.:EP1490024
Date:18.01.2012
Language:EN
[2012/03]
Search report(s)International search report - published on:EP18.09.2003
ClassificationIPC:A61K31/663, A61K9/46
[2011/28]
CPC:
A61K45/06 (EP,US); A61K31/341 (EP,US); A61K31/4164 (EP,US);
A61K31/426 (EP,US); A61K31/4439 (EP,US); A61K31/663 (EP,US);
A61K9/0007 (EP,US) (-)
C-Set:
A61K31/341, A61K2300/00 (EP,US);
A61K31/4164, A61K2300/00 (US,EP);
A61K31/426, A61K2300/00 (US,EP);
A61K31/4439, A61K2300/00 (US,EP);
A61K31/663, A61K2300/00 (EP,US)
(-)
Former IPC [2011/18]A61K31/341, A61K31/4164, A61K31/426
Former IPC [2005/01]A61K9/00, A61K31/663
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/01]
TitleGerman:BRAUSETABLETTEN, ENTHALTEND ALENDRONAT[2011/18]
English:EFFERVESCENT COMPOSITIONS COMPRISING ALENDRONATE[2011/18]
French:COMPOSITIONS EFFERVESCENTES CONTENANT DE L'ALENDRONATE[2011/18]
Former [2005/01]BRAUSETABLETTEN, ENTHALTEND BISPHOSPHONATE, UND DEREN GEBRAUCH ZUR MEDIZINISCHEN BEHANDLUNG
Former [2005/01]EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO
Former [2005/01]COMPOSITIONS EFFERVESCENTES CONTENANT DES BISPHOSPHONATES ET METHODES CONNEXES
Entry into regional phase06.10.2004National basic fee paid 
06.10.2004Designation fee(s) paid 
06.10.2004Examination fee paid 
Examination procedure06.10.2004Amendment by applicant (claims and/or description)
06.10.2004Examination requested  [2004/53]
13.04.2007Despatch of a communication from the examining division (Time limit: M06)
07.09.2007Reply to a communication from the examining division
03.04.2009Despatch of a communication from the examining division (Time limit: M04)
12.08.2009Reply to a communication from the examining division
13.10.2009Despatch of a communication from the examining division (Time limit: M04)
05.02.2010Reply to a communication from the examining division
12.04.2011Despatch of a communication from the examining division (Time limit: M02)
05.05.2011Reply to a communication from the examining division
27.07.2011Communication of intention to grant the patent
01.12.2011Fee for grant paid
01.12.2011Fee for publishing/printing paid
Divisional application(s)EP10010775.4  / EP2277503
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.04.2007
Opposition(s)19.10.2012No opposition filed within time limit [2012/52]
Fees paidRenewal fee
01.04.2005Renewal fee patent year 03
29.03.2006Renewal fee patent year 04
27.06.2007Renewal fee patent year 05
14.03.2008Renewal fee patent year 06
13.03.2009Renewal fee patent year 07
15.03.2010Renewal fee patent year 08
15.03.2011Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.03.200503   M06   Fee paid on   01.04.2005
31.03.200705   M06   Fee paid on   27.06.2007
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.03.2003
BE18.01.2012
CY18.01.2012
CZ18.01.2012
EE18.01.2012
FI18.01.2012
NL18.01.2012
RO18.01.2012
SI18.01.2012
SK18.01.2012
IE06.03.2012
LU06.03.2012
MC31.03.2012
BG18.04.2012
PT18.05.2012
[2014/34]
Former [2014/27]BE18.01.2012
CY18.01.2012
CZ18.01.2012
EE18.01.2012
FI18.01.2012
NL18.01.2012
RO18.01.2012
SI18.01.2012
SK18.01.2012
IE06.03.2012
LU06.03.2012
MC31.03.2012
BG18.04.2012
PT18.05.2012
Former [2013/08]BE18.01.2012
CY18.01.2012
CZ18.01.2012
EE18.01.2012
FI18.01.2012
NL18.01.2012
RO18.01.2012
SI18.01.2012
SK18.01.2012
IE06.03.2012
MC31.03.2012
BG18.04.2012
PT18.05.2012
Former [2012/50]BE18.01.2012
CY18.01.2012
CZ18.01.2012
EE18.01.2012
FI18.01.2012
NL18.01.2012
RO18.01.2012
SI18.01.2012
SK18.01.2012
MC31.03.2012
BG18.04.2012
PT18.05.2012
Former [2012/49]BE18.01.2012
CY18.01.2012
CZ18.01.2012
EE18.01.2012
FI18.01.2012
NL18.01.2012
RO18.01.2012
SI18.01.2012
MC31.03.2012
BG18.04.2012
PT18.05.2012
Former [2012/48]BE18.01.2012
CY18.01.2012
EE18.01.2012
FI18.01.2012
NL18.01.2012
MC31.03.2012
BG18.04.2012
PT18.05.2012
Former [2012/47]BE18.01.2012
CY18.01.2012
FI18.01.2012
NL18.01.2012
MC31.03.2012
BG18.04.2012
PT18.05.2012
Former [2012/41]BE18.01.2012
CY18.01.2012
FI18.01.2012
NL18.01.2012
BG18.04.2012
PT18.05.2012
Former [2012/37]BE18.01.2012
FI18.01.2012
NL18.01.2012
BG18.04.2012
PT18.05.2012
Former [2012/35]BE18.01.2012
NL18.01.2012
BG18.04.2012
Former [2012/33]BE18.01.2012
Cited inInternational search[XY]GB2153225  (GENTILI IST SPA) [X] 1,10-21,23-25,32-35 * the whole document * [Y] 30,31,40-42;
 [Y]US5393531  (GERHARD GERGELY [AT], et al) [Y] 1-43 * column 1, lines 28-34 ** column 1, line 53 - column 2, line 7; example 10 *;
 [Y]US5415870  (GERGELY GERHARD [AT], et al) [Y] 4,7,28,29 * column 1, lines 27-34; examples 6,7 *;
 [XY]WO9744017  (MERCK & CO INC [US], et al) [X] 1,10-21,23-25,32-35 * the whole document * [Y] 30,31,40-42;
 [XY]US2001002395  (DAIFOTIS ANASTASIA G [US], et al) [X] 1-3,5,6,8-14,19,22-24,26,27,32-39 * abstract * * paragraph [0002] * * paragraph [0007] * * paragraph [0014] * * paragraph [0017] * * paragraph [0033] * * paragraph [0035] * * paragraphs [0070] - [0100] * * sentences 7,8, paragraph 101 * * paragraphs [0108] - [0111] * * claims 1,12,14,18,28 * [Y] 4,7,28,29;
 [Y]WO0139724  (UNIV CALIFORNIA SAN DIEGO [US], et al) [Y] 30,31,40-42 * abstract * * page 15, lines 12-14 *;
 [Y]  - GERTZ B J ET AL, "STUDIES OF THE ORAL BIOAVAILABILITY OF ALENDRONATE", CLINICAL PHARMACOLOGY & THERAPEUTICS, MOSBY-YEAR BOOK, ST LOUIS, MO, US, (199509), vol. 58, no. 3, ISSN 0009-9236, pages 288 - 298, XP001006243 [Y] 1-43 * abstract * * page 294, column L, paragraph 3 - column R, paragraph 2 *

DOI:   http://dx.doi.org/10.1016/0009-9236(95)90245-7
by applicantUS4462982
 US4687662
 US4710384
 US4942039
 US5178878
 US5348745
 US5415870
 US5480652
 US5709886
 US5853759
 US5994329
 US6015801
 US6225294
 EP1127573
 US6284272
 US6333316
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.